1. SP has been diagnosed with metastatic squamous cell non-small cell lung cancer. Along with platinum-based doublet chemotherapy,___________________ is recommended as first-line treatment.

2. Patients with adenocarcinoma of the lung who are positive for ROS1 alteration should be considered for ________________________ as first-line therapy?

3. JM is 45-year-old man with EGFR-mutation positive lung cancer successfully treated with erlotinib. After 9 months, radiography reveals the presence of new tumors in his lungs and liver. Re-biopsy reveals the presence of the EGFR T790M mutation. What course of treatment would be MOST APPROPRIATE for this patient?

4. Which of the following is NOT a common adverse event associated with ALK tyrosine kinase inhibition?

5. Resistance to tyrosine kinase inhibitors develops in the majority of patients after a period of approximately_______________.

« Return to Activity